CLINICAL NEUROSCIENCE AND NEUROPATHOLOGYEfficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptomsHuang, Xiaoa; Li, Chaob; Luo, Yan-lic; Wang, Biaob; Ji, Jian-linaAuthor Information aDepartment of Psychological Medicine, Zhongshan Hospital, Fudan University bShanghai Mental Health Center, Shanghai Jiaotong University cDepartment of Psychiatry, Tongji Hospital of Tongji University, Shanghai, China Chao Li, co-first author. The paper entitled ‘Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms’ had been accepted for poster presentation (number CG12P-0179) at the 25th ECNP Congress, 13–17 October 2012, Vienna, Austria, and the abstract had been published in a supplement to the journal, European Neuropsychopharmacology (ENP). Correspondence to Jian-lin Ji, MD, Department of Psychological Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China Tel: +86 216 404 1990; fax: +86 216 404 1991; e-mail: [email protected] Received January 23, 2013 Accepted February 9, 2013 NeuroReport: May 8, 2013 - Volume 24 - Issue 7 - p 364-369 doi: 10.1097/WNR.0b013e3283601a3e Buy Metrics Abstract Pain is the most common symptom reported in both the general population and the general medical setting. The aim of this study is to evaluate the effectiveness, tolerance, and safety of venlafaxine extended-release (XR) monotherapy in treating first-episode outpatients fulfilling the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) criteria for major depressive disorder with associated painful physical symptoms. Of the 102 outpatients enrolled, 86 (84.3%) completed the study. Venlafaxine XR treatment (75–225 mg/day) was followed by a significant decrease in the total scores for the 17-item Hamilton Depression Rating Scale from baseline to the second weekend (t value=16.12, P<0.0001) and at every subsequent visit (weeks 4, 6, and 8, all P<0.0001). Significant differences were also found in the mean Visual Analog Scales for overall pain and the mean medical outcomes study pain measures from baseline to the second weekend (t value=14.99, P<0.0001; t value=12.59, P<0.0001) and at every visit (all P<0.0001). At the end of the eighth week, venlafaxine XR achieved response and remission rates of 68.6 and 40.2%, respectively. The remission rate for pain responders (improvement in Visual Analog Scale overall pain from baseline to last observation ≥50%) was significantly greater than that for pain nonresponders (56.1 vs. 20.0%, P<0.0001). The most common (≥10%) adverse events were nausea (31.4%), dizziness (26.5%), and somnolence (22.5%). Venlafaxine XR is possibly an effective and safe option in the treatment of depression and associated painful physical symptoms. © 2013 Lippincott Williams & Wilkins, Inc.